Hemab Therapeutics (NASDAQ:COAG) Stock Rated “Outperform” in New Coverage at Lifesci Capital

Posted by George Bondi on Nov 9th, 2026

Lifesci Capital began coverage on shares of Hemab Therapeutics (NASDAQ:COAG – Get Free Report) in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage set an “outperform” rating and a $65.00 price target on the stock. Lifesci Capital‘s price objective indicates a potential upside of 32.60% from the company’s previous close.

A number of other equities analysts also recently commented on COAG. Rodman & Renshaw began coverage on shares of Hemab Therapeutics in a research note on Monday, October 12th. They issued a “buy” rating and a $56.00 target price on the stock. Jefferies Financial Group upped their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Weiss Ratings lowered Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th. JPMorgan Chase & Co. started coverage on Hemab Therapeutics in a report on Thursday, October 15th. They set an “overweight” rating and a $70.00 target price on the stock. Finally, Wedbush boosted their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

View Our Latest Research Report on Hemab Therapeutics

Hemab Therapeutics Stock Performance

NASDAQ:COAG opened at $49.02 on Monday. The stock has a market cap of $2.29 billion and a price-to-earnings ratio of -1.98. The company has a 50-day moving average price of $37.50. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $55.42.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities analysts predict that Hemab Therapeutics will post -3.10 earnings per share for the current year.

Hedge Funds Weigh In On Hemab Therapeutics

A number of institutional investors have recently added to or reduced their stakes in COAG. Citadel Advisors LLC purchased a new position in Hemab Therapeutics in the 2nd quarter valued at about $19,226,000. Braidwell LP purchased a new stake in shares of Hemab Therapeutics during the second quarter worth about $5,877,000. State Street Corp purchased a new stake in shares of Hemab Therapeutics during the second quarter worth about $2,825,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics in the second quarter worth about $1,750,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Hemab Therapeutics in the second quarter worth about $688,000.

Hemab Therapeutics Company Profile

(Get Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.